We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

GlaxoSmithKline Czech Republic

Pharmaceutical > Czech Republic > GlaxoSmithKline Czech Republic
Change Company
GlaxoSmithKline Czech Republic

GlaxoSmithKline, s.r.o. is a Czech Republic-based subsidiary of the British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical Company by revenues. The Company was established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham plc. GSK manufactures drugs and vaccines for major disease areas such

Read more »
GlaxoSmithKline, s.r.o. is a Czech Republic-based subsidiary of the British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical Company by revenues. The Company was established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham plc. GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental health conditions, the biggest selling of which were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal.

Buy all financials of GlaxoSmithKline Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
                5,828 5,735 5,653 4,855 4,378    
                622 710 653 596 497    
                291 216 169 119 127    
                240 164 127 87.7 125    
                19.3% 12.0% 9.41% 6.64% 9.44%    
                5.00% 3.76% 2.98% 2.46% 2.91%    
                4.12% 2.86% 2.25% 1.81% 2.85%    
                264 262 239 246 183    

balance sheet

                3,166 2,418 2,374 2,019 2,107    
                41.0 57.7 47.5 33.7 18.8    
                3,084 2,321 2,295 1,959 2,066    
                1,363 1,369 1,340 1,301 1,338    
                1,802 1,050 1,034 718 768    
                55.0 59.5 91.3 61.5 55.7    
                1,747 990 943 656 713    
                0.438 1.02 1.69 -0.001 -3.71    
                9.97% 17.5% 23.8% -0.015% -38.5%    
...               1.64% 1.09% 1.94% 1.42% ... ... ...

cash flow

          ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    

Download Data
income statement Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
Dividends CZK mil
                5,828 5,735 5,653 4,855 4,378    
                5,207 5,026 5,000 4,259 3,880    
                622 710 653 596 497    
                284 315 335 349 298    
                27.6 161 129 107 61.1    
                310 234 189 139 139    
                19.3 18.3 19.9 20.2 11.6    
                291 216 169 119 127    
                4.67 3.27 5.44 2.27 1.37    
                0.000 0.000 0.000 0.000 -30.0    
                286 212 163 117 156    
                46.4 48.6 35.8 29.3 25.6    
                0.000 0.000 0.000 0.000 0.000    
                240 164 127 87.7 125    
... ... ... ... ... ... ... ... ... ... ... ... 125   ...

growth rates

...               -5.48% -1.59% -1.43% -14.1% -9.83%    
...               -34.4% 52.8% -2.39% -1.60% -21.5%    
...               27.4% -24.7% -19.4% -26.0% -0.486%    
...               31.9% -25.9% -21.8% -29.3% 6.70%    
...               32.4% -25.9% -23.1% -28.4% 33.3%    
...               45.3% -31.8% -22.2% -31.2% 42.1%    

ratios

                19.3% 12.0% 9.41% 6.64% 9.44%    
...               14.3% 9.26% 6.91% 5.65% 11.2%    
                10.7% 12.4% 11.5% 12.3% 11.4%    
                5.33% 4.08% 3.34% 2.87% 3.17%    
                5.00% 3.76% 2.98% 2.46% 2.91%    
                4.12% 2.86% 2.25% 1.81% 2.85%    
... ... ... ... ... ... ... ... ... ... ... ... 100%   ...
...               1.64% 1.09% 1.94% 1.42% ... ... ...
                0.438 1.02 1.69 -0.001 -3.71    

Download Data
balance sheet Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

balance sheet

                41.0 57.7 47.5 33.7 18.8    
                37.0 50.5 38.6 20.3 11.6    
                3.56 6.73 8.41 12.9 6.78    
                3,084 2,321 2,295 1,959 2,066    
                1,677 1,163 1,250 813 667    
                1,114 1,025 918 659 663    
                226 0.438 0.680 0.193 515    
                3,166 2,418 2,374 2,019 2,107    
                1,363 1,369 1,340 1,301 1,338    
                0.000 0.000 0.000 0.000 0.000    
                1,802 1,050 1,034 718 768    
                55.0 59.5 91.3 61.5 55.7    
                0.000 0.000 0.000 0.000 0.000    
...   ... ... ... ... ... ... ... ... ... ... ... ... ...
                1,747 990 943 656 713    
                362 240 320 0.000 0.000    
                1,094 445 332 289 347    
                55.0 57.3 85.1 56.3 51.5    
                3,166 2,418 2,374 2,019 2,107    

growth rates

...               15.9% -23.6% -1.81% -15.0% 4.34%    
...               21.4% 0.377% -2.06% -2.90% 2.83%    
...               -18.8% 76.2% 33.3% -100% 266,920%    
...               74.0% -33.7% 33.3% -100% ... ... ...

ratios

                362 240 320 0.000 0.000    
                136 240 319 -0.193 -515    
                1,697 1,744 1,837 1,184 983    
                1,739 1,801 1,884 1,218 1,002    
                9.97% 17.5% 23.8% -0.015% -38.5%    
...               1.64% 1.09% 1.94% 1.42% ... ... ...

Download Data
cash flow Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

cash flow

                240 164 127 87.7 125    
                19.3 18.3 19.9 20.2 11.6    
...         ... ... ... ... ... ... ... ...    
...         ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ...    
...         ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    
          ... ... ... ... ... ... ... ...    

ratios

                69.8 65.3 59.3 49.6 55.2    
                118 84.4 91.3 69.7 62.7    
                76.7 32.3 24.2 24.7 32.6    
                111 117 126 94.5 85.4    
                259 182 147 108 136    
          ... ... ... ... ... ... ... ...    

Download Data
other data Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

other data

                8.14% 5.87% 5.32% 3.99% 6.04%    
                10.7% 12.4% 11.5% 12.3% 11.4%    
                264 262 239 246 183    
                5,062 5,117 5,978 5,537 5,678    
                89,532 100,080 116,960 118,335 135,534    
                5.12% 5.70% 6.12% 7.38% 7.00%    
                16.2% 22.9% 21.9% 25.0% 16.4%    
          ... ... ... ... ... ... ... ...    
                2,325 2,423 2,348 1,780 1,501    
                39.9% 42.2% 41.5% 36.7% 34.3%    
... ...             0.588 0.000 0.000 0.000 3.09    
                1,960 2,042 2,026 1,529 1,281    
                3,503 3,313 3,305 3,075 2,874    
                365 380 322 252 220    

Download Data
Comparison of 9 Companies in Czech Pharmaceutical Companies

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file

Read more »

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file contains data of following companies:

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

Download a sample excel file attached to see more details. On purchase, the hidden cells will be unlocked and all available data wll be visible.

GlaxoSmithKline Czech Republic in Numbers

This Annual Statistical Dossier offers a summary of GlaxoSmithKline Czech Republic's performance between 2003 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you

Read more »

This Annual Statistical Dossier offers a summary of GlaxoSmithKline Czech Republic's performance between 2003 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

GlaxoSmithKline Czech Republic at a Glance

GlaxoSmithKline, s.r.o. is a Czech Republic-based subsidiary of the British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical Company by revenues. The Company was established in 2000 by the merger of Glaxo Wellcome and SmithKline

Read more »

GlaxoSmithKline, s.r.o. is a Czech Republic-based subsidiary of the British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical Company by revenues. The Company was established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham plc. GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental health conditions, the biggest selling of which were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal.

This report offers a summary of the company's performance in 2003-2013. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

GlaxoSmithKline Czech Republic in Numbers

GlaxoSmithKline, s.r.o. is a Czech Republic-based subsidiary of the British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical Company by revenues. The Company was established in 2000 by the merger of Glaxo Wellcome and SmithKline

Read more »

GlaxoSmithKline, s.r.o. is a Czech Republic-based subsidiary of the British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical Company by revenues. The Company was established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham plc. GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental health conditions, the biggest selling of which were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal.

This excel file offers a summary of the company's performance in 2003-2013. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

GlaxoSmithKline Czech Republic made a net profit of CZK 65.4 mil in 2017, up 72.0% when compared to the last year. Total sales reached CZK 2,897 mil, which is down 14.6% when compared to the previous year.

Historically, the company’s

Read more »

GlaxoSmithKline Czech Republic made a net profit of CZK 65.4 mil in 2017, up 72.0% when compared to the last year. Total sales reached CZK 2,897 mil, which is down 14.6% when compared to the previous year.

Historically, the company’s net profit reached an all time high of CZK 240 mil in 2011 and an all time low of CZK -7.67 mil in 2006.

In terms of sales, GlaxoSmithKline Czech Republic reached an all time high of CZK 6,186 mil in 2009 and an all time low of CZK 2,897 mil in 2017.

GlaxoSmithKline Czech Republic's net profit has grown -16.8% a year on average in the last five years while sales have increased by -12.8% a year since 2012.

The firm generated its shareholders an average return on invested capital of 6.67% in the last five years.

As far as GlaxoSmithKline Czech Republic's peers are concerned, Bayer Czech Republic posted a net profit and sales of CZK 106 mil and CZK 4,180 mil in 2017 and Amgen Czech Republic generated a net profit of CZK 37.8 mil (with sales of CZK 417 mil).

You can see all the company’s data at GlaxoSmithKline Czech Republic Profile, or you can download a report on the company in the report section.

GlaxoSmithKline Czech Republic made a net profit of CZK CZK 65.4 mil under revenues of CZK 2,897 mil in 2017, up 72% and -14.6%, respectively, when compared to the last year.

This translates into a net margin of 2.26%. Historically,

Read more »

GlaxoSmithKline Czech Republic made a net profit of CZK CZK 65.4 mil under revenues of CZK 2,897 mil in 2017, up 72% and -14.6%, respectively, when compared to the last year.

This translates into a net margin of 2.26%. Historically, the firm’s net margin reached an all time high of 4.12% in 2011 and an all time low of -0.197% in 2006. The average net margin in the last five years amounted to 2.06%.

On the operating level, EBITDA margin reached 3.10% and EBIT amounted to 3.36% of sales in 2017.

As far as GlaxoSmithKline Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at GlaxoSmithKline Czech Republic Profile, or you can download a report on the company in the report section.

GlaxoSmithKline Czech Republic made a net profit of CZK 65.4 mil under revenues of CZK 2,897 mil in 2017, up 72.0% and -14.6%, respectively, when compared to the last year. This translates into a net margin of 2.26%.

Historically,

Read more »

GlaxoSmithKline Czech Republic made a net profit of CZK 65.4 mil under revenues of CZK 2,897 mil in 2017, up 72.0% and -14.6%, respectively, when compared to the last year. This translates into a net margin of 2.26%.

Historically, the firm’s net profit reached an all time high of CZK 240 mil in 2011 and an all time low of CZK -7.67 mil in 2006. Since 2012, the firm's net profit has increased -60.1% or -16.8% a year on average.

On the operating level, EBITDA reached CZK 97.4 mil, up 56.0% when compared to the previous year. Over the last five years, company's EBITDA has grown -16.1% a year on average.

As far as GlaxoSmithKline Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at GlaxoSmithKline Czech Republic Profile, or you can download a report on the company in the report section.

GlaxoSmithKline Czech Republic's net debt reached CZK -209 mil and accounted for -13.8% of equity at the end of 2017. The ratio is up 40.1% when compared to the previous year.

Historically, the firm’s net debt to equity reached

Read more »

GlaxoSmithKline Czech Republic's net debt reached CZK -209 mil and accounted for -13.8% of equity at the end of 2017. The ratio is up 40.1% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 40.0% in 2008 and an all time low of -38.5% in 2015.

When compared to EBITDA, net debt amounted to -2.15x at the end of the year. The ratio reached an all time high of 2.74 in 2008 and an all time low of -5.61 in 2016.

As far as GlaxoSmithKline Czech Republic's peers are concerned, Bayer Czech Republic posted net debt to equity of 94.4%x and 2.49x when compared to EBITDA at the end of 2017. Amgen Czech Republic ended the year 2017 with a net debt at -0.147%x of equity and -0.006x when compared to its EBITDA while Amgen Czech Republic had net debt at -0.147%x of equity and -0.006x to EBITDA at the end of the year.

You can see all the company’s data at GlaxoSmithKline Czech Republic Profile, or you can download a report on the company in the report section.

See all charts of the company »
GlaxoSmithKline CR's employees fell 14.5% to 141 in 2017
GlaxoSmithKline CR's net profit rose 72.0% to CZK 65.4 mil in 2017
GlaxoSmithKline CR's net profit rose 72.0% to CZK 65.4 mil in 2017
GlaxoSmithKline CR's Capital Expenditures fell 71.6% to CZK 2.22 mil in 2017
GlaxoSmithKline CR's Total Cash From Operations rose 45.1% to CZK -78.2 mil in 2017
GlaxoSmithKline CR's Net Debt/EBITDA rose 61.7% to -2.15 in 2017
GlaxoSmithKline CR's Cash & Cash Equivalents fell 40.3% to CZK 209 mil in 2017
GlaxoSmithKline CR's ROCE rose 59.4% to 5.87% in 2017
GlaxoSmithKline CR's Net Margin rose 101% to 2.26% in 2017